Sumamry
Ajulemic acid, also known as DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, Resunab, or Lenabasum, is a synthetic cannabinoid that exhibits anti-fibrotic and anti-inflammatory properties in pre-clinical research without inducing a subjective “high.” While its design was inspired by delta-9-THC metabolites, such as delta-9-THC-11-oic acid, academic acid is an analog of delta-8-THC metabolite, delta-8-THC-11-oic acid.
This compound is under development for treating inflammatory and fibrotic conditions like systemic sclerosis, dermatomyositis, and cystic fibrosis. Unlike some other cannabinoids, it doesn’t have anti-emetic effects, but it shows promise in addressing chronic inflammatory conditions that fail to resolve. Common side effects include dry mouth, fatigue, and dizziness. Ajulemic acid’s mechanism of action involves CB2 receptor activation, leading to the production of specialized pro-resolving eicosanoids such as lipoxin A4 and Prostaglandin J2.
In animal studies, doses of up to 40 mg/kg of academic acid have demonstrated minimal psychoactivity compared to tetrahydrocannabinol. A formulation of academic acid, known as Lenabasum (formerly Anabasum or Resunab), is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) to treat rare, chronic, and life-threatening inflammatory diseases.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 137945-48-3 |
|---|---|
| PubChem CID | 3083542 |
| ChemSpider | 21106251 |
| UNII | OGN7X90BT8 |
| ChEMBL | ChEMBL456341 |
| CompTox Dashboard (EPA) | DTXSID40900959 |
| Chemical and physical data | |
| Formula | C25H36O4 |
| Molar mass | 400.559 g·mol−1 |
FAQ
1. What is Ajulemic Acid?
Ajulemic acid, also known by various names such as Lenabasum, Anabasum, and Resunab, is a synthetic cannabinoid. It has shown anti-inflammatory and anti-fibrotic effects in research studies and is distinct for not causing a subjective “high.”
2. How does Ajulemic Acid differ from other cannabinoids?
Ajulemic acid is a synthetic cannabinoid that was designed based on delta-9-THC metabolites. It is specifically an analog of the delta-8-THC metabolite, delta-8-THC-11-oic acid. Unlike many other cannabinoids, it does not produce the characteristic euphoria associated with cannabis.
3. What medical conditions is Ajulemic Acid being developed to treat?
Ajulemic acid is being developed for the treatment of inflammatory and fibrotic conditions. Some conditions it may be effective for include systemic sclerosis, dermatomyositis, and cystic fibrosis.
4. Does Ajulemic Acid have any psychoactive effects?
Studies have shown that Ajulemic acid has minimal psychoactivity, especially when compared to tetrahydrocannabinol (THC), which is known for its psychoactive effects. This makes it an attractive option for therapeutic use.
5. What is the mechanism of action of Ajulemic Acid?
Ajulemic acid’s mechanism of action involves the activation of the CB2 receptor. This activation leads to the production of specialized pro-resolving eicosanoids, including lipoxin A4 and Prostaglandin J2, which contribute to its anti-inflammatory effects.
6. Are there any side effects associated with Ajulemic Acid?
Common side effects of Ajulemic acid may include dry mouth, fatigue, and dizziness. As with any medication, individuals may react differently, so it’s essential to monitor and discuss any side effects with a healthcare provider.
7. Is Ajulemic Acid available for medical use?
Ajulemic acid is developing and may not be readily available for general medical use. It is typically under investigation in clinical trials for its effectiveness and safety in treating specific conditions.
8. What is Lenabasum, and how is it related to Ajulemic Acid?
Lenabasum is a formulation of Ajulemic acid developed by Corbus Pharmaceuticals (formerly JB Therapeutics). It is being studied as a potential treatment for rare, chronic, and life-threatening inflammatory diseases.
9. Can Ajulemic Acid be legally obtained for personal use?
The legal availability of Ajulemic acid for personal use may vary by jurisdiction and regulatory status. It is essential to comply with local laws and regulations regarding the use and acquisition of this compound.
10. How promising is Ajulemic Acid in treating inflammatory diseases?
Ajulemic acid shows promise in pre-clinical studies for treating inflammatory and fibrotic conditions, but its clinical effectiveness is still being evaluated. Continued research will determine its potential in managing various medical conditions.
References
- In August 2004, Burstein SH and his team conducted a study on ajulemic acid, a novel cannabinoid known for producing analgesia without the associated “high.” This research, published in “Life Sciences,” shed light on its potential pain-relieving properties. [DOI: 10.1016/j.lfs.2004.04.010] [PMID: 15240185]
- In February 2007, Vann RE, Cook CD, Martin BR, and Wiley JL explored the cannabimimetic properties of ajulemic acid. Their findings, published in “The Journal of Pharmacology and Experimental Therapeutics,” delved into its cannabinoid-like characteristics. [DOI: 10.1124/jpet.106.111625] [PMID: 17105826] [S2CID: 15593252]
- Motwani MP, Bennett F, Norris PC, and their colleagues, in an October 2018 study featured in “Clinical Pharmacology and Therapeutics,” uncovered the potent anti-inflammatory and pro-resolving effects of Anabasum (ajulemic acid) in a human model of self-resolving acute inflammation. [DOI: 10.1002/cpt.980] [PMC: 6175297] [PMID: 29238967]
- In July 2005, Mitchell VA, Aslan S, Safaei R, and Vaughan CW examined the effect of ajulemic acid on rat models of neuropathic and inflammatory pain in “Neuroscience Letters.” Their research provided insights into its potential for pain management. [DOI: 10.1016/j.neulet.2005.03.019] [PMID: 15925096] [S2CID: 582590]
- In June 2005, Burstein S detailed the synthesis, proof of principle, toxicity studies, and clinical trials related to ajulemic acid (IP-751) in “The AAPS Journal.” This comprehensive study explored various aspects of ajulemic acid. [DOI: 10.1208/aapsj070115] [PMC: 2751505] [PMID: 16146336]
- The year 2007 saw the work of Vann RE, Cook CD, Martin BR, and Wiley JL again as they investigated the cannabimimetic properties of ajulemic acid in “The Journal of Pharmacology and Experimental Therapeutics.” Their research contributed to understanding its cannabinoid-like effects. [DOI: 10.1124/jpet.106.111625] [PMC: 2633725]
- Corbus Pharmaceuticals, a company of significance, is actively developing Ajulemic acid for potential therapeutic applications, making it a notable player in the field of cannabinoid research and drug development. [Source: www.lifescienceleader.com]